PNC-28
Also known as: PNC-28
PNC-28 is an experimental p53-derived anticancer peptide closely related to PNC-27, studied for selective membrane disruption of tumor cells. It is a laboratory research compound only, with no approved clinical use.
Last updated
Mechanism of Action
PNC-28 combines a p53-derived sequence with a penetratin (Antennapedia) membrane-transduction domain. Like PNC-27, it is reported to target HDM-2 aberrantly present at the cancer cell membrane and to form transmembrane pores that trigger selective necrosis. The cytotoxic effect is thought to be largely transcription-independent and driven by membrane permeabilization. All current data derive from in vitro and animal experiments.
- Half-life
- Not well characterized; expected short for a linear peptide
- Administration Routes
- subcutaneous, intramuscular
- Research Status
- Preclinical
Reported Benefits
- Studied for selective anticancer cytotoxicity in laboratory models
- Reported preferential killing of tumor cells over normal cells
- Investigated as a membrane-targeting peptide therapeutic concept
- Serves as a research tool alongside PNC-27 for mechanism studies
Potential Side Effects
- No established human safety data
- Potential off-target membrane toxicity
- Possible immunogenicity and local reactions
- Unknown in vivo systemic effects
Common Dosing
For laboratory research use only and not medical advice: studies use micromolar in vitro concentrations or microgram-range animal dosing; no validated human dose exists.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Any human therapeutic use outside controlled research
- Pregnancy and breastfeeding
- Known peptide hypersensitivity
- View
PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo
2006
- View
The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells
2008
- View
Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells
2001
- View
Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells
2024
- View
P53-Derived peptides conjugation to PEI: an approach to producing versatile and highly efficient targeted gene delivery carriers into cancer cells.
2016